Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
| Τίτλος | Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Karavasilis, V., Kosmidis P., Syrigos K. N., Mavropoulou P., Dimopoulos M. A., Kotoula V., Pectasides D., Boukovinas I., Klouvas G., Kalogera-Fountzila A., Papandreou C. N., Fountzilas G., & Briasoulis E. |
| Journal | Anticancer Res |
| Volume | 34 |
| Issue | 10 |
| Pagination | 5649-55 |
| Date Published | 2014 Oct |
| ISSN | 1791-7530 |
| Λέξεις κλειδιά | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Erlotinib Hydrochloride, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Quinazolines, Risk Factors, Taxoids, Treatment Outcome |
| Abstract | AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC).PATIENTS AND METHODS: Patients were randomized to receive daily erlotinib for 12 consecutive days prior to docetaxel (Arm A) or after docetaxel (Arm B). Progression-free survival (PFS) was the primary end-point; secondary end-points were overall survival (OS) and objective response rate (ORR).RESULTS: Fifty eligible patients received a total of 226 treatment cycles (median: 3). Median PFS and OS were 3.6 months and 10.5 months, respectively (differences were not statistically significant between the two arms). Neutropenia grade 3 and 4 occurred in 15 patients, while two patients developed grade 3 diarrhea. There were two treatment-related deaths (pulmonary embolism and non-neutropenic sepsis).CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. |
| Alternate Journal | Anticancer Res. |
| PubMed ID | 25275069 |
